Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They currently have a $200.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 36.05% from the […]

Related Keywords

Bridgewater ,Nova Scotia ,Canada ,Michaelw Bonney , ,Jpmorgan Chase Co ,Steward Partners Investment Advisory ,Harbor Capital Advisors Inc ,Alnylam Pharmaceuticals Inc ,Wolfe Research ,Analyst Recommendations For Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals ,Vanguard Personalized Indexing Management ,Royal Bank ,Alnylam Pharmaceuticals Trading Down ,Needham Company ,Bridgewater Associates ,Insider Transactions At Alnylam Pharmaceuticals ,Wells Fargo Company ,News Ratings For Alnylam Pharmaceuticals Daily ,Get Free Report ,Wells Fargo ,Pharmaceuticals Trading Down ,Director Michael ,Capital Advisors ,Financial Advisors ,Personalized Indexing Management ,Partners Investment Advisory ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Reiterated Rating ,Needham Company Llc ,